A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis

BACKGROUND: Melanoma therapy has changed dramatically over the last decade with improvements in immunotherapy, yet many patients do not respond to current therapies. This novel vaccine strategy may prime a patient’s immune system against their tumor and work synergistically with immunotherapy agains...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Vreeland, Timothy J., Clifton, Guy T., Hale, Diane F., Chick, Robert C., Hickerson, Annelies T., Cindass, Jessica L., Adams, Alexandra M., Bohan, Phillip M. Kemp, Andtbacka, Robert H. I., Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Terando, Alicia M., Wagner, Thomas, Peoples, George E., Faries, Mark B.
বিন্যাস: Online প্রবন্ধ পাঠ‍্য
ভাষা:English
প্রকাশিত: Springer International Publishing 2021
বিষয়গুলি:
Melanoma
অনলাইন ব্যবহার করুন:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914039/
https://www.ncbi.nlm.nih.gov/pubmed/33641012
http://dx.doi.org/10.1245/s10434-021-09709-1

আন্তর্জাল

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914039/
https://www.ncbi.nlm.nih.gov/pubmed/33641012
http://dx.doi.org/10.1245/s10434-021-09709-1

অনুরূপ উপাদানগুলি